Proposed US legislation aimed at patent thickets unlikely to boost biologics competition

The Biologic Patent Transparency Act seeks to accelerate biosimilar entry, but leaves key litigation issues unaddressed and would confer only marginal benefits on imitators


Get unlimited access to all IAM content